Literature DB >> 22712702

Bystander effect in tumor cells produced by Iodine-125 labeled human lymphocytes.

Omar Mamlouk1, Pichumani Balagurumoorthy, Ketai Wang, S James Adelstein, Amin I Kassis.   

Abstract

PURPOSE: To investigate the ability of human lymphocytes labeled with DNA-incorporated (125)I to exert an inhibitory (antiproliferative) bystander effect on co-cultured human colon adenocarcinoma LS174T cells in vitro.
MATERIALS AND METHODS: Human peripheral blood lymphocytes were stimulated to synthesize DNA in the presence of phytohemagglutinin (PHA) and labeled with 5-[(125)I]iodo-2'-deoxyuridine. Human colon adenocarcinoma LS174T cells were co-cultured with the (125)I-labeled lymphocytes in various ratios for 5 days and the proliferation of the LS174T cells was assessed. Further, the supernatant media from these co-cultures were: (i) Transferred to LS174T cells and their proliferation measured after 5 days, (ii) used to assess the clonogenic survival of LS174T cells, and (iii) screened for factors that suppress growth.
RESULTS: A significant reduction in the proliferation of LS174T cells was observed when co-cultured either with (125)I-labeled lymphocytes (56 ± 3.5%) or the supernatant media (52.5 ± 1.3%) obtained from these co-cultures. Clonogenic survival of LS174T cells grown in the supernatant media corroborated the decrease in tumor cell growth.
CONCLUSION: The observed reduction in the proliferation of LS174T cells in presence of (125)I-labeled lymphocytes or media obtained from such co-cultures can be attributed to an inhibitory (antiproliferative) bystander effect, probably mediated by factor(s) released from the dying (125)I-labeled lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22712702      PMCID: PMC3755763          DOI: 10.3109/09553002.2012.702297

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  61 in total

1.  The effector cells in human peripheral blood mediating mitogen-induced cellular cytotoxicity and antibody-dependent cellular cytotoxicity.

Authors:  D L Nelson; B M Bundy; H E Pitchon; R M Blaese; W Strober
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

2.  Cancer therapy with Auger electrons: are we almost there?

Authors:  Amin I Kassis
Journal:  J Nucl Med       Date:  2003-09       Impact factor: 10.057

Review 3.  The radiation-induced bystander effect: evidence and significance.

Authors:  Edouard I Azzam; John B Little
Journal:  Hum Exp Toxicol       Date:  2004-02       Impact factor: 2.903

4.  The range of high LET effects from 125I decays.

Authors:  D E Charlton
Journal:  Radiat Res       Date:  1986-08       Impact factor: 2.841

5.  Technetium-99m-labeled lymphocytes: a radiotoxicity study.

Authors:  T Merz; J Tatum; J Hirsch
Journal:  J Nucl Med       Date:  1986-01       Impact factor: 10.057

Review 6.  The significance of chromosomal aberrations in indium-111-labeled lymphocytes.

Authors:  M L Thakur; J G McAfee
Journal:  J Nucl Med       Date:  1984-08       Impact factor: 10.057

7.  The response of human peripheral blood lymphocytes to phytohemagglutinin: determination of cell numbers.

Authors:  C C Stewart; S F Cramer; P G Steward
Journal:  Cell Immunol       Date:  1975-04       Impact factor: 4.868

8.  PHA-induced cytotoxicity of human lymphocytes against adherent hela cells.

Authors:  G Huges-Law; G C de Gast; T H The
Journal:  J Immunol Methods       Date:  1978       Impact factor: 2.303

9.  TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism.

Authors:  Dong-Wan Seo; Hongmei Li; Liliana Guedez; Paul T Wingfield; Tere Diaz; Rita Salloum; Bei-yang Wei; William G Stetler-Stevenson
Journal:  Cell       Date:  2003-07-25       Impact factor: 41.582

Review 10.  Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development.

Authors:  C V Hojilla; F F Mohammed; R Khokha
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

View more
  1 in total

1.  What is the Role of the Bystander Response in Radionuclide Therapies?

Authors:  Darren Brady; Joe M O'Sullivan; Kevin M Prise
Journal:  Front Oncol       Date:  2013-08-19       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.